Enveric Biosciences, Inc. (ENVB)
After hours:
| Previous close | 0.9000 |
| Open | 0.8700 |
| Bid | 0.6055 x 200 |
| Ask | 1.1000 x 200 |
| Day's range | 0.8400 - 0.8850 |
| 52-week range | 0.6490 - 6.9800 |
| Volume | |
| Avg. volume | 4,781,858 |
| Market cap | 6.127M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.0900 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 23 Apr 2008 |
| 1y target est | 8.00 |
Business WireEnveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
CAMBRIDGE, Mass., May 15, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter of 2024 ended March 31, 2024.
Business WireEnveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
CAMBRIDGE, Mass., May 14, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs ("NPP") to Vancouver, BC-based MindBio Therapeutics (CNSX: MBIO)("MindBio"), a clinical stage biopharma company, which
Business WireEnveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
CAMBRIDGE, Mass., May 08, 2024--Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company ("Licensee") to exclusively out-license two patent families of Methods for Treating Breast Cancer and Other Cancers f
